Small molecule compounds and monoclonal antibody therapy in lung cancer

The leading cause of cancer-related mortality worldwide is lung cancer, with ongoing challenges in treatment efficacy and safety, but recent advances have been made in targeted therapies, including small molecule inhibitors and monoclonal antibodies, have significantly improved treatment precision and reduced side effects compared to traditional methods. Despite these developments, gaps remain in fully understanding resistance mechanisms and identifying novel therapeutic targets. This paper reviews the current state of targeted therapies for lung cancer, examining their mechanisms, clinical applications, and impact on patient outcomes. It provides valuable insights into how these therapies have advanced the field and highlights areas where further research is needed. Future studies should focus on addressing these gaps and exploring new approaches to optimize treatment and enhance patient survival rates.